Edition:
United Kingdom

Verastem Inc (VSTM.OQ)

VSTM.OQ on NASDAQ Stock Exchange Global Market

5.33USD
23 May 2018
Change (% chg)

$0.01 (+0.19%)
Prev Close
$5.32
Open
$5.33
Day's High
$5.47
Day's Low
$5.23
Volume
246,248
Avg. Vol
148,549
52-wk High
$5.71
52-wk Low
$1.93

Chart for

About

Verastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company's advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company's... (more)

Overall

Beta: 2.23
Market Cap(Mil.): $171.64
Shares Outstanding(Mil.): 36.99
Dividend: --
Yield (%): --

Financials

  VSTM.OQ Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -1.24 -- --
ROI: -65.61 1.57 14.38
ROE: -67.03 2.43 16.07

BRIEF-Verastem Oncology Announces Public Offering Of 7.78 Mln Common Shares Priced At $4.50per Share

* VERASTEM ONCOLOGY ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

16 May 2018

BRIEF-Verastem Oncology Announces Public Offering Of Common Stock

* VERASTEM ONCOLOGY ANNOUNCES PUBLIC OFFERING OF COMMON STOCK

15 May 2018

BRIEF-Verastem Oncology Reports Q1 Loss Per Share Of $0.41

* VERASTEM ONCOLOGY REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

03 May 2018

BRIEF-Verastem Reports Year-End 2017 Financial Results

* VERASTEM - EXPECTS TO HAVE SUFFICIENT CASH, CASH EQUIVALENTS AND INVESTMENTS TO FUND CURRENT OPERATING PLAN AND CAPEX REQUIREMENTS INTO H2 2018 Source text for Eikon: Further company coverage:

13 Mar 2018

BRIEF-Verastem Submits Marketing Application To FDA For Duvelisib

* VERASTEM SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR DUVELISIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA AND FOLLICULAR LYMPHOMA

07 Feb 2018

BRIEF-Verastem Presents Preclinical Data Highlighting The Effects Of Duvelisib In Combination With Immune Checkpoint Or Co-Stimulatory Antibodies In B Cell Lymphoma Model

* VERASTEM PRESENTS PRECLINICAL DATA AT ASCO-SITC HIGHLIGHTING THE SYNERGISTIC EFFECTS OF DUVELISIB IN COMBINATION WITH IMMUNE CHECKPOINT OR CO-STIMULATORY ANTIBODIES IN B CELL LYMPHOMA MODEL

26 Jan 2018

BRIEF-Verastem Announces Increased Hercules Debt Facility

* VERASTEM INC - ANNOUNCED ENTRY INTO AN AMENDMENT TO ITS LOAN AND SECURITY AGREEMENT WITH HERCULES CAPITAL INC

04 Jan 2018

BRIEF-Verastem Announces Pricing Of Public Offering Of Common Stock

* VERASTEM ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

15 Dec 2017

BRIEF-Verastem Announces Public Offering Of Common Stock

* VERASTEM INC - INTENDS TO OFFER AND SELL $25 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING Source text for Eikon: Further company coverage:

14 Dec 2017

BRIEF-‍Verastem Announces Clinical Data From Pivotal Phase 3 Duo Study​

* ‍VERASTEM ANNOUNCES CLINICAL DATA FROM PIVOTAL PHASE 3 DUO™ STUDY​

10 Dec 2017

Earnings vs. Estimates